Literature DB >> 8956341

Applications and simulations of a discontinuous oral absorption pharmacokinetic model.

J W Witcher1, F D Boudinot.   

Abstract

PURPOSE: To illustrate the application of a discontinuous oral absorption model to cimetidine and ranitidine plasma concentration versus time data to demonstrate the use of the model for drugs which display discontinuous oral absorption profiles, and to illustrate the effect of various model parameters on plasma drug concentration versus time profiles and bioavailability.
METHODS: A discontinuous oral absorption model was used to fit ranitidine and cimetidine serum concentrations following oral and intravenous administration. The model was also used to simulate bioavailability and plasma concentrations versus time profiles for various parameter values.
RESULTS: Serum concentrations following administration of ranitidine and cimetidine were well described by the model, and parameter estimates obtained were in agreement with literature values. Simulations demonstrate the effects of various absorption parameters and gastroin-testinal tract transit parameters on bioavailability and plasma concentration profiles.
CONCLUSIONS: This discontinuous oral absorption pharmacokinetic model can be a useful tool in characterizing absorption phases, disposition, and bioavailability of drugs exhibiting two absorption peaks following oral administration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8956341     DOI: 10.1023/a:1016457110726

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon.

Authors:  R L Oberle; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

2.  Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models.

Authors:  K Murata; K Noda; K Kohno; M Samejima
Journal:  J Pharm Sci       Date:  1987-02       Impact factor: 3.534

3.  Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.

Authors:  D R Guay; G R Matzke; H N Bockbrader; J Dancik
Journal:  Clin Pharm       Date:  1983 Mar-Apr

4.  Bioavailability of cimetidine in man.

Authors:  S S Walkenstein; J W Dubb; W C Randolph; W J Westlake; R M Stote; A P Intoccia
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

5.  Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil (L-FMAU) in rats.

Authors:  J D Wright; T Ma; C K Chu; F D Boudinot
Journal:  Biopharm Drug Dispos       Date:  1996-04       Impact factor: 1.627

6.  Ranitidine bioavailability and kinetics in normal male subjects.

Authors:  D C Garg; D J Weidler; F N Eshelman
Journal:  Clin Pharmacol Ther       Date:  1983-04       Impact factor: 6.875

7.  Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.

Authors:  M M Hammarlund; L K Paalzow; B Odlind
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine.

Authors:  M F Williams; G E Dukes; W Heizer; Y H Han; D J Hermann; T Lampkin; L J Hak
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200

9.  Pharmacokinetics of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (L-FMAU) in rats.

Authors:  J D Wright; T Ma; C K Chu; F D Boudinot
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

10.  Site-dependent small intestinal absorption of ranitidine.

Authors:  T Gramatté; E el Desoky; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more
  3 in total

1.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

3.  Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.

Authors:  Ekarat Jantratid; Sompol Prakongpan; Gordon L Amidon; Jennifer B Dressman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.